Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (313)	7/12/1999 1:31:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Stiff coffee, huh? Well, traders just see that the patients went on to die, and they don't understand the trial design or the kinetics whereby donor-specific cells are derived from the marrow stem cells. A complete remission of GvH in ten steroid-resistant patients..... the results are damn good. However, I want to see the actual abstract and, if possible, the presentation graphics. It would have been nice to see a breakdown of the patients, to have gotten a feel for how the four-dose patients looked relative to those dosed for a month beyond the initial four doses. Very good results, no matter how you cut the data. However, looks like tons of work to go for GvH and an effective protocol. I'm more enthusiastic regarding autoimmunity, but it's surface enthusiasm.... we'll know more when we know more. - vbg -